Literature DB >> 2423675

Soluble asparaginase-dextran conjugates show increased circulatory persistence and lowered antigen reactivity.

T E Wileman, R L Foster, P N Elliott.   

Abstract

Oxidized dextrans of increasing molecular weight were bound covalently to Erwinia carotovora asparaginase. The resulting conjugates retained 50% of their enzyme activity and showed marked resistance to proteolysis by trypsin and chymotrypsin and inactivation by asparaginase-specific antibody. When tested in-vivo, the larger molecular weight conjugates showed prolonged circulatory survival in both immune and non-immune animals and failed to elicit full type III hypersensitivity or anaphylactic reactions when injected into sensitized guinea-pigs. Rabbits could tolerate multiple doses of the asparaginase conjugate without developing an immunity to the enzyme. A conjugate showing increased circulatory half-life and lowered antigen reactivity should have therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423675     DOI: 10.1111/j.2042-7158.1986.tb04564.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Intrahepatic delivery of glutathione by conjugation to dextran.

Authors:  Y Kaneo; Y Fujihara; T Tanaka; Y Kozawa; H Mori; S Iguchi
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

2.  Preparation and nanoencapsulation of l-asparaginase II in chitosan-tripolyphosphate nanoparticles and in vitro release study.

Authors:  Elham Bahreini; Khosrow Aghaiypour; Roghayeh Abbasalipourkabir; Ali Rezaei Mokarram; Mohammad Taghi Goodarzi; Massoud Saidijam
Journal:  Nanoscale Res Lett       Date:  2014-07-09       Impact factor: 4.703

3.  Dextramabs: A Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold.

Authors:  Hendrik Schneider; Lukas Deweid; Thomas Pirzer; Desislava Yanakieva; Simon Englert; Bastian Becker; Olga Avrutina; Harald Kolmar
Journal:  ChemistryOpen       Date:  2019-03-28       Impact factor: 2.911

4.  Design of expert guided investigation of native L-asparaginase encapsulated long-acting cross-linker-free poly (lactic-co-glycolic) acid nanoformulation in an Ehrlich ascites tumor model.

Authors:  Manvi Singh; Nazia Hassan; Devina Verma; Pragya Thakur; Bibhu Prasad Panda; Amulya Kumar Panda; Rakesh Kumar Sharma; Aamir Mirza; Sheikh Mansoor; Salman H Alrokayan; Haseeb A Khan; Parvaiz Ahmad; Zeenat Iqbal
Journal:  Saudi Pharm J       Date:  2020-05-06       Impact factor: 4.330

5.  Development and characterization of a novel l-asparaginase/MWCNT nanobioconjugate.

Authors:  Raquel O Cristóvão; Mafalda R Almeida; Maria A Barros; João C F Nunes; Rui A R Boaventura; José M Loureiro; Joaquim L Faria; Márcia C Neves; Mara G Freire; Valéria C Ebinuma-Santos; Ana P M Tavares; Cláudia G Silva
Journal:  RSC Adv       Date:  2020-08-24       Impact factor: 4.036

6.  Potentiation of in vivo antitumor effects of recombinant interleukin-1 alpha by gelatin conjugation.

Authors:  Y Tabata; K Uno; Y Ikada; T Kishida; S Muramatsu
Journal:  Jpn J Cancer Res       Date:  1993-06

Review 7.  Nanotechnological Strategies for Protein Delivery.

Authors:  María Rocío Villegas; Alejandro Baeza; María Vallet-Regí
Journal:  Molecules       Date:  2018-04-25       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.